Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL3110293 | 0.93 | — | — | |
| SCHEMBL2646596 | 0.80 | ALDH1A1 (0.30) | — | |
| SCHEMBL120534 | 0.80 | — | — | |
| SCHEMBL11148671 | 0.80 | ALDH1A1 (0.30) | — | |
| SCHEMBL1600341 | 0.80 | — | — | |
| SCHEMBL11144949 | 0.80 | ALDH1A1 (0.30) | — | |
| Ether SCHEMBL3101249 | 0.78 | — | — | |
| Ether SCHEMBL29012397 | 0.77 | KDM4E (0.31) | SHBG | |
| Water SCHEMBL10976746 | 0.77 | — | — | |
| SCHEMBL6064 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-5510536-A | Production method of tris(pentafluorophenyl)borane using pentafluorophenylmagnesium derivatives prepared from pentafluorobenzene | TOSOH AKZO CORPORATION (JP) | 1996-04-23 | — | — | US | disclosed |
| EP-0706528-A1 | FUCOSYLATED GLYCOSIDES AS INHIBITORS OF BACTERIAL ADHERENCE | Astra Aktiebolag (SE) | 1996-04-17 | — | — | EP | disclosed |
| EP-0604963-A1 | Production method of tris(pentafluorophenyl)borane using pentafluorophenylmagnesium derivatives prepared from pentafluorobenzene | TOSOH AKZO CORPORATION (JP) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | CYP1A2 1570/4885SHBG 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.